KMT2D and lymphoma: Mutational inactivation of CREBBP and KMT2D is thus thought to contribute to lymphoma development by decommissioning enhancer networks that are required for post-GC differentiation while tipping the balance between the oncogenic function of BCL6 at the expense of p53.